areas of infectious diseases, but they do not see it in neurological or psychological disorders. ,lzheimer's, autism, depression schizophrenia. we're trying to figure out ways to get them back into the game, because the science is generating new, great opportunities. we think we have inside the presence that will work in four hours instead of four weeks. we of new treatments for autism, which we think will really make a difference. we're really focused on trying to provide cognitive tools for people with schizophrenia so people can go back to work or finish school. i think there really are great opportunities. the way we're trying to do this now is through a public/private effort. bringing in industry that helps to understand where the opportunities are and to work with the fda, to work with the academic sector, bring government into this as well so what happens in a way that is really being done for the public good, and everyone realizes if we're going to bend at that curb and decrease mortality, morbidity, we have to come up with something better than what we have now. we will provide the